vs
Ladder Capital Corp（LADR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Ladder Capital Corp的1.4倍（$30.3M vs $22.3M），Ladder Capital Corp净利率更高（71.0% vs -221.3%，领先292.4%），REGENXBIO Inc.同比增速更快（43.0% vs -18.0%），Ladder Capital Corp自由现金流更多（$78.7M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -22.5%）
Ladder Capital Corp是一家总部位于美国的领先商业地产金融机构，核心业务包括发放优先级商业抵押贷款、夹层债务，投资商业地产抵押担保证券及直接持有商业地产资产，服务覆盖美国多地的地产所有者、运营商与开发商。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LADR vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$22.3M
营收增速更快
RGNX
高出61.0%
-18.0%
净利率更高
LADR
高出292.4%
-221.3%
自由现金流更多
LADR
多$131.5M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-22.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.3M | $30.3M |
| 净利润 | $15.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 69.5% | -190.0% |
| 净利率 | 71.0% | -221.3% |
| 营收同比 | -18.0% | 43.0% |
| 净利润同比 | -49.4% | -31.2% |
| 每股收益（稀释后） | $0.13 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LADRRGNX
| Q4 25 | $22.3M | $30.3M | ||
| Q3 25 | $27.8M | $29.7M | ||
| Q2 25 | $21.5M | $21.4M | ||
| Q1 25 | $20.3M | $89.0M | ||
| Q4 24 | $27.2M | $21.2M | ||
| Q3 24 | $38.4M | $24.2M | ||
| Q2 24 | $34.3M | $22.3M | ||
| Q1 24 | $37.1M | $15.6M |
净利润LADRRGNX
| Q4 25 | $15.9M | $-67.1M | ||
| Q3 25 | $19.2M | $-61.9M | ||
| Q2 25 | $17.1M | $-70.9M | ||
| Q1 25 | $11.6M | $6.1M | ||
| Q4 24 | $31.3M | $-51.2M | ||
| Q3 24 | $27.6M | $-59.6M | ||
| Q2 24 | $32.1M | $-53.0M | ||
| Q1 24 | $16.4M | $-63.3M |
毛利率LADRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率LADRRGNX
| Q4 25 | 69.5% | -190.0% | ||
| Q3 25 | 72.4% | -176.3% | ||
| Q2 25 | 96.7% | -296.3% | ||
| Q1 25 | 52.7% | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | 74.1% | -256.6% | ||
| Q2 24 | 90.4% | -251.3% | ||
| Q1 24 | 49.4% | -408.8% |
净利率LADRRGNX
| Q4 25 | 71.0% | -221.3% | ||
| Q3 25 | 69.0% | -208.3% | ||
| Q2 25 | 79.5% | -331.8% | ||
| Q1 25 | 56.8% | 6.8% | ||
| Q4 24 | 115.1% | -241.3% | ||
| Q3 24 | 71.7% | -246.3% | ||
| Q2 24 | 93.6% | -237.7% | ||
| Q1 24 | 44.2% | -405.4% |
每股收益（稀释后）LADRRGNX
| Q4 25 | $0.13 | $-1.30 | ||
| Q3 25 | $0.15 | $-1.20 | ||
| Q2 25 | $0.14 | $-1.38 | ||
| Q1 25 | $0.09 | $0.12 | ||
| Q4 24 | $0.25 | $-0.99 | ||
| Q3 24 | $0.22 | $-1.17 | ||
| Q2 24 | $0.26 | $-1.05 | ||
| Q1 24 | $0.13 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $38.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.5B | $102.7M |
| 总资产 | $5.2B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LADRRGNX
| Q4 25 | $38.0M | $230.1M | ||
| Q3 25 | $49.4M | $274.2M | ||
| Q2 25 | $134.9M | $323.3M | ||
| Q1 25 | $479.8M | $267.9M | ||
| Q4 24 | $1.3B | $234.7M | ||
| Q3 24 | $1.6B | $255.5M | ||
| Q2 24 | $1.2B | $290.4M | ||
| Q1 24 | $1.2B | $338.7M |
股东权益LADRRGNX
| Q4 25 | $1.5B | $102.7M | ||
| Q3 25 | $1.5B | $161.5M | ||
| Q2 25 | $1.5B | $213.7M | ||
| Q1 25 | $1.5B | $274.2M | ||
| Q4 24 | $1.5B | $259.7M | ||
| Q3 24 | $1.5B | $301.4M | ||
| Q2 24 | $1.5B | $348.3M | ||
| Q1 24 | $1.5B | $390.7M |
总资产LADRRGNX
| Q4 25 | $5.2B | $453.0M | ||
| Q3 25 | $4.7B | $525.2M | ||
| Q2 25 | $4.5B | $581.0M | ||
| Q1 25 | $4.5B | $490.9M | ||
| Q4 24 | $4.8B | $466.0M | ||
| Q3 24 | $4.8B | $519.1M | ||
| Q2 24 | $4.8B | $569.4M | ||
| Q1 24 | $5.3B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $87.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $78.7M | $-52.8M |
| 自由现金流率自由现金流/营收 | 352.4% | -174.0% |
| 资本支出强度资本支出/营收 | 37.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 5.49× | — |
| 过去12个月自由现金流最近4个季度 | $118.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LADRRGNX
| Q4 25 | $87.0M | $-52.3M | ||
| Q3 25 | $26.3M | $-56.0M | ||
| Q2 25 | $44.0M | $-49.3M | ||
| Q1 25 | $-28.7M | $33.6M | ||
| Q4 24 | $133.9M | $-31.6M | ||
| Q3 24 | $169.0M | $-40.5M | ||
| Q2 24 | $45.4M | $-45.5M | ||
| Q1 24 | $-20.4M | $-55.5M |
自由现金流LADRRGNX
| Q4 25 | $78.7M | $-52.8M | ||
| Q3 25 | $25.9M | $-56.5M | ||
| Q2 25 | $43.4M | $-49.7M | ||
| Q1 25 | $-29.6M | $32.6M | ||
| Q4 24 | $127.4M | $-32.7M | ||
| Q3 24 | $166.0M | $-40.9M | ||
| Q2 24 | $44.9M | $-46.0M | ||
| Q1 24 | $-21.7M | $-56.0M |
自由现金流率LADRRGNX
| Q4 25 | 352.4% | -174.0% | ||
| Q3 25 | 93.1% | -189.9% | ||
| Q2 25 | 201.6% | -232.8% | ||
| Q1 25 | -145.6% | 36.6% | ||
| Q4 24 | 468.2% | -154.2% | ||
| Q3 24 | 432.1% | -168.9% | ||
| Q2 24 | 131.0% | -206.2% | ||
| Q1 24 | -58.6% | -358.5% |
资本支出强度LADRRGNX
| Q4 25 | 37.4% | 1.7% | ||
| Q3 25 | 1.7% | 1.7% | ||
| Q2 25 | 2.9% | 1.8% | ||
| Q1 25 | 4.3% | 1.2% | ||
| Q4 24 | 23.9% | 5.1% | ||
| Q3 24 | 7.8% | 1.3% | ||
| Q2 24 | 1.3% | 2.1% | ||
| Q1 24 | 3.7% | 3.6% |
现金转化率LADRRGNX
| Q4 25 | 5.49× | — | ||
| Q3 25 | 1.37× | — | ||
| Q2 25 | 2.57× | — | ||
| Q1 25 | -2.49× | 5.53× | ||
| Q4 24 | 4.27× | — | ||
| Q3 24 | 6.13× | — | ||
| Q2 24 | 1.41× | — | ||
| Q1 24 | -1.24× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LADR
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
